Related Experiment Video
Updated: Jun 2, 2026
06:04
Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
Published on: March 6, 2018
Effects of pulsed electromagnetic fields on benign prostate hyperplasia
Xenophon K Giannakopoulos1, Christos Giotis, Spyridon Ch Karkabounas
1Urological Clinic, University Hospital, Faculty of Medicine, University of Ioannina, Ioannina, Greece.
International Urology and Nephrology
|May 4, 2011
Summary
Pulsed electromagnetic fields offer a non-invasive treatment for benign prostate hyperplasia (BPH). This study found radiofrequency EMF therapy improved BPH symptoms and urinary flow, with lasting effects.
Area of Science:
- Urology
- Medical Physics
- Electromagnetic Therapy
Background:
- Benign prostate hyperplasia (BPH) is commonly treated with invasive procedures like TUNA, ILC, and HoLRP.
- Investigating non-invasive therapeutic modalities for BPH is crucial for patient well-being and treatment accessibility.
- Electromagnetic field (EMF) exposure presents a potential non-invasive approach for managing BPH symptoms.
Purpose of the Study:
- To evaluate the efficacy of a non-invasive pulsed electromagnetic field (PEMF) therapy at radiofrequencies for treating benign prostate hyperplasia (BPH).
- To compare the outcomes of PEMF therapy with conventional alpha-blocker treatment (Alfusosin) in BPH patients.
- To assess the long-term effects of PEMF therapy on BPH symptoms and urinary function.
Main Methods:
- Twenty male patients diagnosed with BPH were enrolled and randomized into two groups: a control group receiving Alfusosin and an experimental group receiving daily 30-minute PEMF exposure for two weeks.
- The PEMF group was treated with radiofrequency pulsed electromagnetic fields generated by an ion magnetic inductor.
- Patients were assessed pre- and post-treatment using International Prostate Symptom Score (IPSS), ultrasound (U/S) for prostate volume and urine residue, uroflowmetry, and prostate-specific antigen (PSA) levels.
Main Results:
- The PEMF group demonstrated statistically significant improvements in IPSS, prostate volume, urine residue, and mean urine flow rate compared to baseline.
- The Alfusosin group showed improvement only in IPSS, with no significant changes in other measured parameters.
- One-year follow-up confirmed the sustained efficacy of PEMF therapy in the experimental group, indicating lasting benefits.
Conclusions:
- Pulsed electromagnetic field therapy at radiofrequencies is a promising non-invasive treatment option for benign prostate hyperplasia (BPH).
- PEMF therapy offers significant advantages over conventional drug treatment in improving urinary symptoms and flow dynamics in BPH patients.
- The observed long-term positive outcomes suggest that EMF therapy could be a valuable addition to the BPH management armamentarium.
